RHINOMED

RHINOMED TO DELIVER RISING STARS KEYNOTE ADDRESS AT 2015 MASTER INVESTOR UK SHOW

- Number one Investor Show in the UK to be held 25th April 3500 attendees
- Keynote presentation on Rising Star Stage
- RNO Shareholder Sir Steve Redgrave, CBE to guest present alongside CEO Michael Johnson
- Coincides with UK National Stop Snoring Week, 20-25th April, 2015

Melbourne, Australia. March 31st 2015:

Rhinomed (ASX:RNO) is pleased to advise CEO Michael Johnson has been invited to provide the keynote address on the Rising Stars Stage at the 2015 Master Investor Show (<u>www.masterinvestor.co.uk</u>) to be held in London on 25th April, 2015.

Initiated by leading UK investor, Jim Mellon, Master Investor is regarded as the number one Investor Show in the UK and will be attended by approximately 3500 motivated investors, brokers and industry analysts.

Sir Steve Redgrave, CBE, heralded as one of the greatest Olympians of all time, having won 5 consecutive Olympic gold medals, will join Rhinomed on the podium. Sir Steve, who is a long-standing shareholder of Rhinomed and a brand ambassador, will be supporting the company and present alongside Rhinomed CEO Michael Johnson.

The Show coincides with <u>National Stop Snoring</u> Week in the UK, where Rhinomed and Sir Steve will be playing an active role in highlighting Rhinomed's recently released Mute technology that has been shown to reduce snoring and improve sleep quality.

Sleep is fast becoming recognised for its importance in recovery, quality of life and role in performance. "Rhinomed is delighted that Sir Steve can join the company at the Master Investor Show. Sir Steve brings a valuable perspective to the Rhinomed story and appreciates the importance breathing plays in delivering high-level performance and the role it plays in sleep, recovery and health." said CEO Michael Johnson.

Poor sleep is a well-recognised community heath problem, costing billions of dollars every year. It affects quality of life, work productivity, as well as behavior and relationship problems. The company's Mute[®] technology not only reduces snoring but also radically improves sleep quality, by increasing the volume of air travelling through the nose during sleep, preventing congestion and encouraging nasal breathing.

The Master Investor Show is held at the Business Design Centre in London on Saturday 25th April 2015. Rhinomed will present on the Rising Stars Stage at 1.35pm, and will be at Exhibition booth #17 throughout the day. Rhinomed would like to invite shareholders to attend and a limited number of complimentary passes to the Show are available by contacting Rhinomed.

RHINOMED

Media Enquiries Michael Johnson, CEO & Managing Director +61 38416 0900 mjohnson@rhinomed.com.au

Follow us on twitter y @rhinomedceo and @theturbinecom and @mutesnoring

About Rhinomed Limited (ASX:RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology platform in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to: http://www.rhinomed.global

Rhinomed has two applications of its technology on market. Turbine is a sports breathing technology available in leading sports store and at www.theturbine.com. In a little over 12 months Turbine has been accepted by elite athletes as the leading breathing aid to assist in sport and exercise. Mute is a nasal stenting technology shown to reduce the incidence of snoring and improve sleep quality. Mute is available in pharmacies and at www.mutesnoring.com